Castle Biosciences, Inc., a dermatologic diagnostics company providing personalized genomic information to improve treatment decisions, announced that it has received approval from the New York State Department of Health for its proprietary DecisionDx® DiffDx™-Melanoma gene expression profile test.
September 16, 2021
· 6 min read